key: cord-0970551-zkogga87 authors: Thoguluva Chandrasekar, Viveksandeep; Venkatesalu, Bhanuprasad; Patel, Harsh K.; Spadaccini, Marco; Manteuffel, Jacob; Ramesh, Mayur title: Systematic review and meta‐analysis of effectiveness of treatment options against SARS‐CoV‐2 infection date: 2020-07-22 journal: J Med Virol DOI: 10.1002/jmv.26302 sha: 6774d217b48124cc1af8602bb4db3ba3abb19ec2 doc_id: 970551 cord_uid: zkogga87 Treatment options for severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta‐analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS‐CoV‐2. Primary outcome was all‐cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty‐nine studies with 5207 patients were included. Pooled all‐cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%‐17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97‐1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60‐9.45). There was no difference in other secondary outcomes. There is a need for well‐designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options. Prevention data in a cohort of 72 314 patients, clinical deterioration tends to typically occur in the second week of onset of symptoms with need for hospitalization and close monitoring in 14% of patients and around 5% of patients require invasive ventilation. 4 Several therapeutic interventions like Hydroxychloroquine (HCQ), Chloroquine, Remdesivir, Corticosteroids, Tocilizumab, and convalescent plasma therapy have been attempted, but currently, there is no known intervention that has reduced mortality in COVID-19 patients. These questions bring into focus the need of a comprehensive systematic review of the published literature to collate the available evidence. The aim of this systematic review and meta-analysis is to assess if any intervention provides mortality benefit, other clinically relevant outcomes, and also ascertain the safety profile. Items for Systematic Reviews and Meta-Analyses recommendations. 5 The protocol is provided as Appendix 1. Institutional review board approval was not required for this study since no patient identifiers were disclosed. The inclusion criteria were as follows: (a) studies reporting outcomes for treatment in SARS-CoV-2 infection; (b) all studies including randomized controlled trials (RCTs), prospective, retrospective, and case series; (c) full-length studies; (d) patients more than 18 years of age. Exclusion criteria were: (a) preclinical studies, epidemiological, and descriptive studies without intervention for SARS-CoV-2 patients; (b) abstracts. The data were extracted by two authors independently into predefined forms. The following data were extracted from the studies: first author, mean age, study design, number of patients, gender, rates of: mortality, clinical improvement, mechanical ventilation, progression to severe disease, viral clearance, discharge, and adverse events. Data for both intervention and control arms (for available studies) were extracted separately. Quality assessment was performed only for RCTs as most of the other studies were retrospective in nature with short hospital courses for duration of treatment. Cochrane risk bias tool was used for study quality assessment for RCTs. 6 The definitions of outcomes that were assessed are provided in Appendix 3. The intervention arm consisted of patients receiving the drug or the therapeutic intervention while the control arm patients received standard of care treatment for SARS-CoV-2 without a specific intervention. The primary outcomes were the all-cause mortality in the intervention arm and in comparison, with control arm. The secondary outcomes were rates of clinical recovery, need for mechanical ventilation, viral clearance, radiological improvement, discharge, and adverse events in intervention arm and comparison with control arm. Median duration for viral clearance and clinical recovery was also calculated from available studies. Number needed to treat (NNT) and number needed to harm (NNH) were defined as the number of patients who needed to be treated to provide benefit or harm in at least one patient, comparing intervention and control arms for respective outcomes. Percentages for categorical variables and median with interquartile range (IQR) for continuous variables were presented. Differences in medians were calculated using the Mann-Whitney-Wilcoxon test. Proportions with pooled rates with 95% confidence intervals (CIs) were calculated for individual arms. Odds ratios (OR) comparing with control arm were reported with 95% CI and P value of less than .05 was considered statistically significant. Random effects model described by DerSimonian and Laird was used for analysis. Corresponding forest plots were constructed for both primary and secondary outcomes. NNT and NNH were calculated using the inverse of the differences in benefit or harm between the intervention and control arms for the respective outcomes. Study heterogeneity was assessed using Inconsistency index (I 2 statistic) with low, moderate, substantial, and considerable heterogeneity indicated by I 2 value of 0% to 30%, 31% to 60%, 61% to 75%, and 76% to 100%, respectively. All Remdesivir), two were Tocilizumab based single-arm studies, five used corticosteroids (three with control arm) and five studies were singlearm plasma therapy based. There were 3624 patients in the intervention arm (mean age: 55.9 ± 8.4 years, 62% males) and 1583 patients (mean age: 52.5 ± 8.5 years, 60.7% males) in the control arm. The median duration of follow-up was 14 days (IQR: 9-24.5) and the range was 6 to 32 days across all studies. The demographics and study characteristics have been provided in Table 1 . Eight RCTs were part of this meta-analysis. Of these three were at low risk of bias and five were at high risk. Risk of bias summary has been provided in Appendix 4. Twenty-four studies provided data on mortality in the intervention arm and the pooled all-cause in-hospital mortality rate was 12.8% (95% CI: 8.1%-17.4%) for a median follow-up duration of 14 (IQR: 10-18.5) days (Table 2 ). Comparing the mortality between the intervention arm and Figure 2) , did not show a statistically significant difference between the two groups (Appendix Table 1 ). ( Figure 3A ). There was no significant difference in the outcome when analysis was restricted to HCQ and antiviral based studies. Nine studies reported data on worsening of clinical status in the hospital in mild-moderate severity patients, with a pooled rate of 11.6% (95% CI: 5.4%-17.8%) in the intervention arm (n = 387) over a median duration of 13 (IQR: 9.5-19.5) days. Comparing the pooled rates in five studies reporting the outcome in both groups (n = 386), the pooled rates were 13.4% and 12.8% in the intervention and control groups, respectively, with no significant difference between the two groups (OR: 1.19; 95% CI: 0.67-2.13, I 2 = 0%). Subgroup analysis restricted to HCQ based and antiviral studies also did not reveal any significant difference. Sixteen studies (n = 791) reported the rate of adverse events in the intervention group with a pooled adverse event rate of 23.3% (95% CI: 12.1%-34.5%). Six studies (n = 754) compared intervention and control groups with pooled adverse event rates of 34% and 29.5%, respectively, with no significant difference between the two groups (OR: 1.44; 95% CI: 0.70-2.94) (NNT-22) ( Figure 4A ). On subgroup analysis, the incidence of adverse events was significantly higher in the HCQ group (OR: 3.88; 95% CI: 1.60-9.45; I 2 = 0%) ( Figure 4B) with an NNH of 7, but there was no significant difference for studies with antiviral agents. There was also no significant difference between both the groups in radiological improvement and discharge rates. The individual pooled rates and ORs are provided in Table 2 . Subgroup analysis for only RCTs for available outcomes is provided in Appendix Table 2 . disease. 35, 36 An initial case series of 26 patients from France comparing HCQ and control groups suggested that HCQ leads to rapid antiviral clearance in 70% of patients compared to 12.5% in controls. This study was fraught with methodological inconsistencies like enrollment of asymptomatic individuals, omission of six patients from analysis (HCQ patients of whom one died and three were transferred to intensive care unit). 9 In a randomized study of 62 patients from China, patients treated with HCQ showed radiological improvement in resolution of lung lesions as well as reduction in clinical progression of disease. The commonality of the initial studies on HCQ was a relatively small sample size, inappropriate control groups, lack of clarity in defining the study outcomes. 14 Two larger prospective RCTs from France and Brazil show that HCQ/chloroquine use is associated with increased incidence of cardiac events with no survival benefit. 12, 16 In view of conflicting data outcomes, the National Institute of Health (NIH), United States recommends that there is insufficient clinical data to recommend either for or against using chloroquine or HCQ for the treatment of COVID-19. 37 There have also been reports of severe drug reaction with generalized exanthematous pustulosis reported with HCQ use. 38 Despite these issues, HCQ is currently one of the most commonly used medications in various parts of the world. Our analysis shows that HCQ based regimens had increased rate of mortality (NNH-13) and adverse events (NNH-7) compared to control patients. We hope our meta-analysis adds more evidence to dampen its use in view of lack of benefit and increased side effects. Remdesivir was originally designed for use against Ebola. Remdesivir was studied in severe COVID-19 in China showed that the drug did not show any benefit in terms of time to recovery as well as 28-day mortality outcome, though the study was terminated prematurely in view of difficulty in patient accrual. 22 oseltamivir, whose proclaimed efficacy was claimed to be a byproduct of concealed information and aggressive lobbying by pharmaceutical companies. 40 The published or preprint data for other drugs like Favipravir, Baloxavir/Marboxil, corticosteroids, convalescent plasma are currently insufficient to make any specific recommendation and our meta-analysis also suggests the same. Our meta-analysis shows that none of the so far studied inter- The strengths of our study are as follows: we included 29 studies with more than 5200 patients in our analysis with various interventions. Our review is extensive, by including the available interventions and providing clinically relevant outcomes in comparison with controls. Several subgroup analyses were also performed based on study interventions and design. Heterogeneity in most of our outcomes was mild to moderate but we performed subgroup analysis in RCTs to further reduce the heterogeneity. Our study has several limitations. The study design, patient population, and the outcomes assessed were variable in different studies. Even though the intervention arms were clearly defined in most studies, some of the patients in those arms also received other medications and outcomes for such patients could not be excluded separately, which could have confounded the results. Different levels of disease severity of patients on study entry could lead to heterogeneity in outcomes but we tried to address it by performing subgroup analyses based on disease severity for outcomes when possible. Duration of follow-up was variable across studies and entire patient data at the end of study may not have been represented which is a limitation of the published literature. Adverse events reported include medication-related adverse events and also symptoms in both groups, which could be related to SARS-CoV-2, but this was unanimously reported across all studies. The dose of medications, especially HCQ, was variable in studies and dose based analysis could not be performed. Data from prepublished studies were also included in our analysis but we had included them to provide a more comprehensive overview to prevent misinterpretation of results to the best of our capabilities. The results of our study should hence be interpreted with caution keeping these limitations in mind. In this meta-analysis, there was no overall mortality or clinical benefit for THOGULUVA CHANDRASEKAR ET AL. The species Severe acute respiratory syndrome-related coronavirus: classifying. -nCoV and naming it SARS-CoV-2 Mild or moderate COVID-19 Clinical characteristics of coronavirus disease 2019 in China. The Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement The Cochrane collaboration's tool for assessing risk of bias in randomised trials Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial Observational study of hydroxychloroquine in hospitalized patients with covid-19. The No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial Treatment with convalescent plasma for critically Ill patients with SARS Q1-CoV-2 infection Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab treatment in COVID-19: A single center experience Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Compassionate use of remdesivir for patients with severe covid-19. The Treatment with convalescent plasma for COVID-19 patients in Wuhan, China Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19 An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma Treating COVID-19 with chloroquine Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro COVID-19) Treatment Guidelines National Institutes of Health Available at https://wwwcovid19treatmentguidelinesnihgov Generalized pustular figurate erythema: a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine Tug of war for antiviral drugs data Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection The authors declare that there are no conflict of interests.